Summary
Definition
History and exam
Key diagnostic factors
- presence of risk factors
- abdominal distension
- jaundice and pruritus
- blood in vomit (haematemesis) and black stool (melaena)
- hand and nail features (e.g., leukonychia, palmar erythema, spider naevi)
- facial features (e.g., telangiectasia, spider naevi, jaundiced sclera)
- abdominal features (e.g., collateral circulation, hepatosplenomegaly, distension)
- altered mental status
Other diagnostic factors
- constitutional symptoms
- lower extremity swelling
- hepatic fetor
- muscle wasting
- peripheral oedema
- recurrent infections
- decreased libido
- chest wall features (e.g., gynaecomastia)
- dyspnoea
- chest pain
- syncope
Risk factors
- alcohol misuse
- intravenous drug use
- unprotected intercourse
- obesity
- country of birth
- blood transfusion
- tattooing
Diagnostic investigations
1st investigations to order
- liver function tests
- gamma-glutamyl transferase (GGT)
- serum albumin
- serum sodium
- serum potassium
- prothrombin time
- platelet count
- antibodies to hepatitis C virus
- hepatitis B surface antigen ± hepatitis B DNA assay
Investigations to consider
- total iron, total iron binding capacity (TIBC), transferrin saturation, and serum ferritin
- antinuclear antibody
- antismooth muscle antibody
- liver kidney microsomal antibody
- antimitochondrial antibody
- serum immunoglobulins
- serum ceruloplasmin
- plasma alpha-1 antitrypsin
- alpha-fetoprotein
- abdominal ultrasound
- abdominal CT
- abdominal MRI
- upper gastrointestinal endoscopy
- liver biopsy
- imaging-based non-invasive tests
- blood-based non-invasive tests
- portal pressure assessment
Treatment algorithm
all patients
Contributors
Authors
Apostolos Koffas, MD (AUTH), MRCP (UK), FESBGH
Consultant Hepatologist (Locum)
Barts Health NHS Trust
London
UK
Disclosures
AK acts as an advisor for Gilead Sciences.
Patrick T. F. Kennedy, MB, BCh, BAO, BMedSci, FRCP, MD
Professor and Consultant Hepatologist
Barts Liver Centre
Barts and the London School of Medicine and Dentistry
London
UK
Disclosures
PTFK acts as an advisor for Gilead Sciences, Janssen, and Immunocore. PTFK has received grant funding from Gilead Sciences.
Acknowledgements
Dr Apostolos Koffas and Professor Patrick T. F. Kennedy would like to gratefully acknowledge Dr Grace E. Dolman, Dr Keith D. Lindor, and Dr Flavia Mendes, previous contributors to this topic.
Disclosures
GED declares that she has no competing interests. KDL is an unpaid advisor for Intercept Pharmaceuticals and Shire Pharmaceuticals. FM declares that she has no competing interests.
Peer reviewers
Phillipp Hartmann, MD, MAS, DABOM
Assistant Professor - Pediatric Gastroenterology
Hepatology & Nutrition - University of California San Diego
Rady Children’s Hospital San Diego
San Diego
CA
Disclosures
PH declares that he has no competing interests.
James Neuberger, DM, FRCP, Hon
Consultant Physician
Hon Professor in Medicine
Associate Medical Director NHSBT
Queen Elizabeth Hospital
Birmingham
UK
Disclosures
JN declares that he has no competing interests.
Differentials
- Budd-Chiari syndrome
- Portal vein thrombosis
- Splenic vein thrombosis
More DifferentialsGuidelines
- AASLD practice guidance on acute-on-chronic liver failure and the management of critically ill patients with cirrhosis
- AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis
More GuidelinesPatient information
Cirrhosis: what is it?
Cirrhosis: what treatments work?
More Patient informationCalculators
MELDNa scores (for liver transplantation listing purposes, not appropriate for patients under age 12 years) (SI units)
NAFLD Fibrosis Score
More CalculatorsVideos
Abdominal paracentesis animated demonstration
More videos- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer